Shaanxi Panlong Pharmaceutical Faces Evaluation Adjustment Amid Mixed Sector Performance and Rising Costs

Shaanxi Panlong Pharmaceutical Group has recently undergone an evaluation adjustment, reflecting a shift in its overall assessment. This adjustment comes amid a backdrop of mixed technical indicators and a notable performance in the pharmaceuticals and biotechnology sector. The company has experienced a flat financial performance for the quarter ending September 2025, with key metrics indicating challenges in growth. Over the past five years, net sales have increased at an annual rate of 11.84%, while operating profit has seen a growth rate of 6.18%. However, the return on capital employed (ROCE) has reached a low of 7.32%, and the debt-equity ratio has peaked at -60.2%, suggesting potential concerns regarding financial leverage. Additionally, raw material costs have risen by 5.84% year-over-year, which may impact profitability. In terms of market performance, Shaanxi Panlong has generated a return of 13.31% over the last year, significantly trailing behind the China Shanghai Composite's return of 24.98%. This context has contributed to the recent revision in its score, highlighting the complexities facing the company in a competitive market landscape. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.